Does promoter methylation primarily occur in tumor cells of patients with non-small cell lung cancer?
Promoter methylation almost exclusively occurred in tumor cells of patients with NSCLC.
Our data indicate that in the CHB disease model, the immunosuppressive liver environment is down-regulated in the maintained on-treatment long-term remission state and correlates with the intensity of liver inflammation, but not liver T cell restoration.